Patients with DNMT3A mutations had significantly higher ESR and disease-activity scores specifically in patients with seropositive, but not with seronegative, RA (Fig. 5, A and B), suggesting that DNMT3A may contribute to increased inflammatory activity in patients with seropositive RA. This evidence concerns the gene DNMT3A and rheumatoid arthritis.